According to BIS Research, next-generation oncology devices and solutions comprise devices and software leveraging emerging technologies to aid in the diagnosis, treatment, and monitoring of various types of cancer. Emerging technologies refer to technologies that are novel, minimally invasive, and are capable of specifically targeting the tumor cells while sparing healthy tissue.

The recent technological advancement in the field of next-generation sequencing (NGS) and cell and molecular biology has given birth to the new era of precision medicine, which offers a platform to analyze the variability in genes, lifestyle, and environment of each person individually. Now, the researchers have found an even better option through cell sequencing, which precedes the advancements of next-generation sequencing. In the past few decades, whole genome sequencing (WGS) and whole transcriptome sequencing (WTS) methods have been applied to single cells to combine DNA, RNA, protein, and chromatin information through a single cell. The transcriptomics technique has enabled researchers to use genomics, proteomics, transcriptomics, and epigenomics to understand the heterogeneity of genetically identical cells in the same tissue.

CRISPR is a technology that is used in gene editing enabling researchers and scientists globally to alter DNA sequence and modify gene function with ease. CRISPR gene editing was adopted from the antivirus immunity system of single-celled microorganisms, namely archaea and bacteria. Fragments of alien DNA, known as a spacer, are incorporated and transcribed into guide crRNA (CRISPR RNAs) to specifically target and cleave the genome of the virus and other foreign bodies using Cas proteins. In other words, the CRISPR/Cas9 system directs the Cas9 nuclease to form a site-directed double-strand DNA break using a small RNA molecule that results in permanent alterations of the genomic target sequence and repair the damage caused to DNA. These components, when transferred into more complex organisms, enable gene editing or modifications.

The study defines cancer microbiome as the aggregate of microorganisms living in or on the human body along with their genomes that are influencing cancer manifestation and progression. Cancer microbiome sequencing has increasingly become an area of interest for the research community, which has the potential to revolutionize cancer care, largely due to studies that have significantly correlated the microbiome’s involvement in cancer manifestation. This study aims at deciphering the potential of the cancer microbiome sequencing and its larger role in bolstering the current era of precision medicine.

The agriculture industry is one of the biggest and most revenue-generating industries in the world. The agricultural production by the farmers helps in tackling the global food demand, which is expected to increase with the growing population. Farmers worldwide depend on agricultural production for their livelihood, and increased efficiency in the field would help in the upliftment of farmers and an increased global agricultural production. Farm management software and data analytic solutions can play a significant role in the growth of the global agricultural sector.

Epigenetics modification, including histone modification, DNA methylation, and RNA-mediated processes modification, are key to impact gene expression primarily at the level of transcription; disturbing any of three marks that contribute to epigenetic modification can cause abnormal activation or silencing of genes. However, other steps in the process (for example, translation) may also be regulated epigenetically. The current study aims to assess the global epigenetics market by focusing on products (consumables, instruments, software) catering to end users, including pharmaceutical and biotechnology companies, academic and research institutions, contract research organizations (CROs), and other end users. The current market for epigenetics is majorly dominated by manufacturers and service providers such as Thermo Fisher Scientific Inc, Illumina, Inc, Bio-Rad Laboratories, Inc, PerkinElmer Inc, Agilent Technologies, Inc, F. Hoffmann-La Roche Ltd., Exact Sciences Corporation, Merck Group, Abcam plc., MDxHealth, Pacific Biosciences of California, Inc, QIAGEN N.V., Zymo Research Corporation, Active Motif, and Promega Corporation among others.

The study defines that to accelerate the speed of chemical reactions, biological catalysts are required, particularly when there is a need to catalyze reactions that occur within the body of a living being. Ligases are those biological catalysts that seal the ends of enormous molecules like DNA. These enzymes are broadly utilized in molecular cloning, gene synthesis, next-generation sequencing, and many consequent by-products of DNA biotechnology. These enzymes particularly are also used for rectifying dysfunctions and the absence of DNA ligases in humans, which has a huge potential to revolutionize molecular diagnostics and malignant growth detection.